Seminars in Hematology
Volume 47, Issue 1 , Pages 79-85, January 2010

Transplant Outcomes for Primary Immunodeficiency Disease

  • Angela R. Smith

      Affiliations

    • Department of Pediatrics, University of Minnesota Pediatric Blood and Marrow Transplant Program, Minneapolis, MN
  • ,
  • Thomas G. Gross

      Affiliations

    • Department of Pediatrics, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Nationwide Children's Hospital, Columbus, OH
  • ,
  • K. Scott Baker

      Affiliations

    • Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
    • Corresponding Author InformationAddress correspondence to K. Scott Baker, MD, Director, Survivorship Program, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Mailstop D5-280, Seattle, WA 98109-1024

Primary immune deficiencies (PIDs) are rare diseases, and most are lethal without appropriate intervention. Hematopoietic cell transplantation (HCT) can cure the majority of patients, but most lack a suitable matched related donor. Alternative donor stem cells (mismatched related donor bone marrow, unrelated donor bone marrow, and unrelated donor umbilical cord blood [UCB]) are therefore frequently required. Published data comparing outcomes after alternative donor transplant for PID are scarce. The outcomes and potential advantage and disadvantages of each alternative stem cell source are discussed in this chapter. Although there are insufficient prospective data to make meaningful comparisons between the alternative stem cell sources, the results presented here demonstrate clearly that the use of UCB transplantation for PID is a viable option and may be advantageous in many situations.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0037-1963(09)00132-2

doi:10.1053/j.seminhematol.2009.10.001

Seminars in Hematology
Volume 47, Issue 1 , Pages 79-85, January 2010